Dynavax Technologies Corporation
Dynavax Technologies is a biopharmaceutical company dedicated to developing and commercializing novel vaccines to help protect the world against infectious diseases, utilizing proven, innovative adjuvant technology. They focus on developing vaccines like HEPLISAV-B® for hepatitis B and have a broad pipeline of vaccines to prevent infectious diseases.
Industries
Nr. of Employees
large (251-1000)
Dynavax Technologies Corporation
Berkeley, California, United States, North America
Products
HEPLISAV-B (hepatitis B vaccine, recombinant, adjuvanted)
Recombinant hepatitis B vaccine formulated with a TLR9‑targeting oligonucleotide adjuvant for prevention of hepatitis B virus infection in adults.
CpG 1018 adjuvant (TLR9 agonist)
A clinically studied synthetic CpG oligonucleotide adjuvant that targets TLR9 to enhance antibody and T‑cell responses; used in licensed hepatitis B vaccine and made available for partner development programs.
HEPLISAV-B (hepatitis B vaccine, recombinant, adjuvanted)
Recombinant hepatitis B vaccine formulated with a TLR9‑targeting oligonucleotide adjuvant for prevention of hepatitis B virus infection in adults.
CpG 1018 adjuvant (TLR9 agonist)
A clinically studied synthetic CpG oligonucleotide adjuvant that targets TLR9 to enhance antibody and T‑cell responses; used in licensed hepatitis B vaccine and made available for partner development programs.
Services
Adjuvant licensing and supply (TLR9 oligonucleotide adjuvant)
Partnerships to provide a clinically studied TLR9 oligonucleotide adjuvant to research institutions and vaccine developers for use in adjuvanted vaccine programs.
Contract manufacturing, process development and technology transfer
Manufacturing services including recombinant antigen production, process development, GMP production, and transfer of manufacturing technologies to partner facilities.
Clinical development and trial collaboration
Design and execution of clinical trials for vaccine candidates, including observer‑blinded, randomized and controlled Phase 1/2 and Phase 2 studies.
Adjuvant licensing and supply (TLR9 oligonucleotide adjuvant)
Partnerships to provide a clinically studied TLR9 oligonucleotide adjuvant to research institutions and vaccine developers for use in adjuvanted vaccine programs.
Contract manufacturing, process development and technology transfer
Manufacturing services including recombinant antigen production, process development, GMP production, and transfer of manufacturing technologies to partner facilities.
Clinical development and trial collaboration
Design and execution of clinical trials for vaccine candidates, including observer‑blinded, randomized and controlled Phase 1/2 and Phase 2 studies.
Expertise Areas
- Vaccine research and development
- Adjuvant discovery and development (TLR‑targeted)
- Clinical trial management
- GMP manufacturing and CMC
Key Technologies
- Toll-like receptor (TLR) agonists (TLR9; TLR7/TLR8)
- Synthetic CpG oligonucleotides (TLR9 agonists)
- Yeast-based recombinant protein expression (Hansenula polymorpha)
- Adjuvant formulation and nanoparticle conjugates